ClinicalTrials.gg
CompletedNCT05790889Updated Oct 21, 2026

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

A Phase 1/2 interventional study of Rabies vaccine and RH5.1 10μg adjuvated with 50μg Matrix-M in Malaria,Falciparum, sponsored by University of Oxford. Completed at 1 site in Burkina Faso. Open to participants aged 5 Months to 17 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University of Oxford · Phase 1/2, Interventional, and Prevention

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
5 Months to 17 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Malaria, Falciparum by University of Oxford — 3 open to participants now, 9 under way, 1 of them phase 3. Malaria, Falciparum · University of Oxford.

Enrollment
10th of 47
390 · median 62
Started
2023
with 5 others
Phase 1/2
12 of 54
none open now
Registered
44th of 54
by date

Among the 54 studies in Malaria, Falciparum by University of Oxford, this one is the 10th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2023, is one of 12 in phase 1/2, and was the 44th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

3 of the 54 studies in Malaria, Falciparum by University of Oxford are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 5 Months to 17 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Malaria, Falciparum by University of Oxford, or all of them as a file.
02

Study summary

This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso

Read the detailed description

During the initial recruitment to Groups 1 and 2, participants will be randomised 1:2 to receive vaccination with the rabies control vaccination or RH5.1/Matrix-M.

During recruitment to Groups 3, 4 and 5, participants will be randomised 1:2:2 to receive vaccination with rabies control vaccination, RH5.1/Matrix-M or RH5.2-VLP/Matrix-M Efficacy of vaccination will be assessed by comparing the incidence of malaria cases in the pooled control groups (Groups 1 and 3) to the incidence of malaria in each investigational vaccine group (Groups 2,4 and 5).

There are three study vaccines: the IMP, 10μg RH5.1 adjuvanted with Matrix-M; 5μg RH5.2-VLP and Rabies Vaccine. Participants will receive the first vaccination of RH5.1 10μg with 50μg Matrix-M (Groups 2 and 4) or RH5.2 5μg with 50μg Matrix-M (Group 5). After approximately 4 weeks, a second dose will be administered, followed by a third and final vaccination approximately 4 weeks later (Groups 3-5) or approximately 4 months later (Groups 1-2). Second and third vaccinations will be administered at the same dose of both vaccine and adjuvant as at the initial vaccination and will be given within the window period of 5 months. Volunteers will be followed for 12 months from final vaccination.

The trial is funded by EDCTP grant number RIA2016V-1649-MMVC and by a Wellcome Trust Translational Award (205981/Z/17/Z)

03

Conditions studied

  • Malaria,Falciparum

Browse trials for

04

Who can participate

Ages eligible
5 Months to 17 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infant aged 5-17 months at the time of first study vaccination
  2. Parent/guardian provides signed/thumb-printed
  3. Infant and parent/guardian resident in the study area villages and anticipated to be available for vaccination and follow-up for 12 months following last dose of vaccination.

Exclusion criteria

Exclusion Criteria:

  • congenital abnormalities as judged by the PI or other delegated individual.
  • Clinically significant skin disorder (psoriasis, contact dermatitis etc.), cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness as judged by the PI or other delegated individual.
  • Weight-for-age Z score of less than -3 or other clinical signs of malnutrition.
  • History of allergic reaction, significant IgE-mediated event, or anaphylaxis to immunization.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • Sickle cell disease.
  • Clinically significant laboratory abnormality as judged by the study clinician.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
  • Receipt of any vaccine in the 7 days preceding enrolment, or planned receipt of any other vaccine within 7 days following each study vaccination.
  • History of vaccination with another malaria vaccine.
  • Participation in another research study involving receipt of an product in the 30 days preceding enrolment, or planned use during the study period.
  • Known maternal infection (no testing will be done by the study team).
  • Any confirmed or suspected or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (for , this will mean prednisone, or equivalent, ≥0.5 mg/kg/day; inhaled and topical steroids are allowed).
  • Any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
390 participants (actual)

Study arms

  • Placebo comparator
    Group 1 (Control group)

    n= 60. Age= 5-17 months Rabies Vaccine administered on Days 0, 28 and 152.

    Biological: Rabies vaccine

  • Experimental
    Group 2

    n=120 Age= 5-17 months First vaccination of RH5.1 10μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 152.

    Biological: RH5.1 10μg adjuvated with 50μg Matrix-M

  • Placebo comparator
    Group 3 (Control Group)

    n= 60. Age= 5-17 months Rabies Vaccine administered on Days 0, 28 and 56.

    Biological: Rabies vaccine

  • Experimental
    Group 4

    n=120 Age= 5-17 months First vaccination of RH5.1 10μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 56.

    Biological: RH5.1 10μg adjuvated with 50μg Matrix-M

  • Experimental
    Group 5

    n=120 Age= 5-17 months First vaccination of RH5.2-VLP 5μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 56.

    Biological: RH5.2 5μg adjuvated with 50μg Matrix-M

Interventions

  • BiologicalRabies vaccine

    Vaccine

  • BiologicalRH5.1 10μg adjuvated with 50μg Matrix-M

    Vaccine

  • BiologicalRH5.2 5μg adjuvated with 50μg Matrix-M

    Vaccine

06

What researchers measure

Primary outcomes

  1. To assess the protective efficacy against clinical malaria of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area for 6 months after the last vaccination.

    Time to first episode of clinical malaria (defined as the presence of axillary temperature higher than 37.5 degree celsius and P. Falciparum parasite density \>5000 asexual forms/µL)

    Time frame: From 14 days after the third study vaccination until 6 months after the third study vaccination.

  2. To assess the safety and reactogenicity of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area.

    Occurrence of solicited systemic reactogenicity signs and symptoms via clinic and home visits

    Time frame: The month following each vaccination and at 6 and 12 months after administration of the final dose of vaccine.

Secondary outcomes

  1. To assess the humoral immunogenicity of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area.

    The following measures will be assessed * Serum ELISA response: 1\. Quantitative antigen-specific IgG antibody levels (µg/mL readout) over time - analysis of peak responses and longevity; 2. Antigen-specific antibody subclass/isotype measurement; 3. Antigen-specific antibody avidity measurement; In vitro GIA against 3D7 clone P. falciparum parasites using purified total IgG and a single-cycle pLDH readout assay * Purified IgG ELISA versus GIA titration "Quality Analysis"

    Time frame: Immunology blood samples will be collected at screening, day of vaccination (V) 1, 14 & 28 days post V2, day of V3, 14 days post V3, 2, 6 and 12 months post V3.

  2. To assess the protective efficacy against clinical malaria of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area for 3 months after the last vaccination.

    Time to first episode of clinical malaria (defined as the presence of axillary temperature ≥37.5°C and P. falciparum parasite density \>5000 asexual forms/µL).

    Time frame: From 14 days after the third study vaccination until 3 months after the third study vaccination

  3. To assess the protective efficacy against clinical malaria of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area

    Occurrence of solicited local reactogenicity signs and symptoms via clinic and home visits

    Time frame: For 12 months after the last vaccination

  4. To assess the protective efficacy against asymptomatic P. falciparum infection of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area, by qPCR.

    Efficacy tested by conducting qPCR analysis

    Time frame: At 6 and 12 months after administration of the final dose of vaccine.

  5. To assess the protective efficacy against asymptomatic P. falciparum infection against gametocytaemia of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area, by qPCR.

    The proportion of participants in each study arm that show presence of parasite density \>5000 asexual forms/µL as measured by quantitative reverse-transcriptase PCR PLUS presence of axillary temperature \<37.5°C and absence of history of fever within the last 24 hours. The proportion of participants in each study arm that show presence of parasite density \>0 asexual forms/µL as measured by quantitative reverse-transcriptase PCR PLUS presence of axillary temperature \<37.5°C and absence of history of fever within the last 24 hours.

    Time frame: At 6 and 12 months post third study vaccination.

  6. To assess the protective efficacy against clinical malaria of RH5.1 in Matrix-M and RH5.2-VLP in Matrix-M in 5-17 months old children living in a malaria-endemic area for 12 months after the last vaccination.

    Time to first episode of clinical malaria (defined as the presence of axillary temperature ≥37.5°C and P. falciparum parasite density \>5000 asexual forms/µL).

    Time frame: From 14 days after the third study vaccination until 12 months after the third study vaccination

  7. To assess the protective efficacy against gametocytaemia of RH5.1 in Matrix-M and RH5.2-VLP in Matrix-M in 5-17 months old children living in a malaria-endemic area, by qPCR at 2 and 6 months after administration of the final dose of vaccine

    The proportion of participants in each study arm that show presence of gametocytes \>0 gametocytes/μL as measured by quantitative reverse-transcriptase PCR.

    Time frame: At 2 and 6 months post third study vaccination.

  8. Efficacy against incident severe anaemia and blood transfusion requirement

    The proportion of participants in each study arm with documented Hb \<5.0 g/dL identified at clinical presentation in association with P. falciparum asexual parasitaemia \> 5000 parasites/µL. The proportion of participants in each study arm with documented Hb \<5.0 g/dL identified at clinical presentation and requirement for a blood transfusion.

    Time frame: From 14 days after the third study vaccination until 6 months after the third study vaccination.

07

Study locations

1 site
  • Institut de Recherche en Sciences de la Santé
    Siglé, Boulkiemdé Province BP 7192 OUAGADOUGOU 03, BF, Burkina Faso
08

References and documents

Publications

  • Natama HM, Salkeld J, Some A, Soremekun S, Diallo S, Traore O, Rouamba T, Ouedraogo F, Ouedraogo E, Dabone KCS, Kone NA, Compaore ZMJ, Kafando M, Bonko MDA, Konate F, Sorgho H, Nielsen CM, Pipini D, Diouf A, King LDW, Shaligram U, Long CA, Cho JS, Lawrie AM, Skinner K, Roberts R, Miura K, Bradley J, Silk SE, Draper SJ, Tinto H, Minassian AM. Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children. Lancet Infect Dis. 2025 May;25(5):495-506. doi: 10.1016/S1473-3099(24)00752-7. Epub 2024 Dec 10. PubMed 39672183 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Oct 2026, 42 months.

Of 13 phase 1/2 interventional studies under Malaria, Falciparum, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 42 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion May 2026 → Oct 2026 and completion May 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Mar 30, 2023
StartActual
Apr 3, 2023
Primary completionActual
Oct 16, 2026was May 2026
CompletionActual
Oct 16, 2026was May 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 21, 2026
Sites
1 site added, 1 site removed
Show site
  • Institut de Recherche en Sciences de la Santé · Siglé, Burkina Faso
Show 1 removed
  • Institut de Recherche en Sciences de la Santé · Sigle, Burkina Faso
Oct 21, 2026
Primary completion
May 30, 2026→Oct 16, 2026 (actual)
Oct 21, 2026
Study completion
May 30, 2026→Oct 16, 2026 (actual)
Oct 21, 2026
Enrollment
480 (estimated)→390 (actual)
Oct 21, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39672183 ↗
Oct 21, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionTo assess the humoral immunogenicity of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area.: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39672183 ↗
    1 site added, 1 site removed
    Show site
    • Institut de Recherche en Sciences de la Santé · Siglé, Burkina Faso
    Show 1 removed
    • Institut de Recherche en Sciences de la Santé · Sigle, Burkina Faso
    Primary completion May 30, 2026→Oct 16, 2026 (now actual)
    Study completion May 30, 2026→Oct 16, 2026 (now actual)
    Enrollment 480 (estimated)→390 (actual)
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionTo assess the humoral immunogenicity of RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in 5-17 months old children living in a malaria-endemic area.: how it is measured was reworded
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05790889
Collaborators
Institut de Recherche en Sciences de la Sante, Burkina Faso, European and Developing Countries Clinical Trials Partnership (EDCTP), Wellcome Trust
Responsible party
Sponsor
First posted
Mar 30, 2023
Start date
Apr 3, 2023
Primary completion
Oct 16, 2026
Completion
Oct 16, 2026
Last update
Oct 21, 2026

Study contacts

Angela Minassian
principal investigator · Honorary Consultant and Chief Investigator - Project clinical trials

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion